Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://flyinmiata.com
Are you over 18 and want to see adult content?
A complete backup of https://robertheaton.com
Are you over 18 and want to see adult content?
A complete backup of https://smilingmind.com.au
Are you over 18 and want to see adult content?
A complete backup of https://mobilbranche.de
Are you over 18 and want to see adult content?
A complete backup of https://oec-paris.fr
Are you over 18 and want to see adult content?
A complete backup of https://californiababy.com
Are you over 18 and want to see adult content?
A complete backup of https://seenthis.co
Are you over 18 and want to see adult content?
A complete backup of https://fiveable.me
Are you over 18 and want to see adult content?
A complete backup of https://mtgereit.biz
Are you over 18 and want to see adult content?
A complete backup of https://kcoyle.net
Are you over 18 and want to see adult content?
A complete backup of https://brookfieldcommunitiesalberta.ca
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of jamiemagazine.nl
Are you over 18 and want to see adult content?
A complete backup of windarranger.com
Are you over 18 and want to see adult content?
A complete backup of smartbloggerz.com
Are you over 18 and want to see adult content?
A complete backup of mathgames-online.com
Are you over 18 and want to see adult content?
A complete backup of meherpurbarta.com
Are you over 18 and want to see adult content?
A complete backup of manisahaliyikama.co
Are you over 18 and want to see adult content?
Text
Meninges.
DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologicPOSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA.ATH-1017 | ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the biotechSEMORINEMAB
Overview. Name: Semorinemab Synonyms: RO7105705 , MTAU9937A, RG6100 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AC Immune SA, Genentech, Hoffmann-La Roche Background. This is an anti-tau IgG4 antibody that grew out of a research collaboration between AC Immune and LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.GANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aAMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion of INGESTED AΒ TRIPS TRANSFORMATION IN MICROGLIA A fluorescent dye, X04 binds Aβ fibrils. Grubman and colleagues extracted the animals’ brains two hours later, and used fluorescence-activated cell sorting to isolate microglia with and without the dye. They found that 13.5 and 15.8 percent of microglia were actively gobbling Aβ in the brains of 4- and 6-month-old mice,respectively.
ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Algorithm Bests Humans in Predicting Alzheimer’s. Add To My AlzForum. 27 May 2021. A person's blood phospho-tau level, combined with his or her APOE genotype and scores on executive function and memory tests, outperforms the clinician in predicting dementia within the next four years. As Mice Age, T Cells Traipse Around TheirMeninges.
DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologicPOSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA.ATH-1017 | ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the biotechSEMORINEMAB
Overview. Name: Semorinemab Synonyms: RO7105705 , MTAU9937A, RG6100 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AC Immune SA, Genentech, Hoffmann-La Roche Background. This is an anti-tau IgG4 antibody that grew out of a research collaboration between AC Immune and LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.GANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aAMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion of INGESTED AΒ TRIPS TRANSFORMATION IN MICROGLIA A fluorescent dye, X04 binds Aβ fibrils. Grubman and colleagues extracted the animals’ brains two hours later, and used fluorescence-activated cell sorting to isolate microglia with and without the dye. They found that 13.5 and 15.8 percent of microglia were actively gobbling Aβ in the brains of 4- and 6-month-old mice,respectively.
ALL NEWS | ALZFORUM
iNDI Aims to Standardize Human Stem Cell Research. Add To My AlzForum. 06 May 2021. The iPSC Neurodegenerative Disease Initiative is creating 100+ isogenic cell lines. Each carries a different risk variant for Alzheimer's or a related dementia. Scientists around the world can obtain the cells through Jackson Labs.ALL NEWS | ALZFORUM
Aducanumab Approved to Treat Alzheimer’s Disease. Add To My AlzForum; 17 Comments; 07 Jun 2021. Biogen got the go-ahead under the FDA’s accelerated approval pathway, which requires change in a surrogate biomarker and Phase 4 studies to verify a clinical benefit.ALL NEWS | ALZFORUM
Neuronal Exosomes Embroiled in Controversy. Add To My AlzForum; 3 Comments; 10 Jun 2021. The L1CAM cell adhesion marker is a widelyadopted marker of
CONFERENCE CALENDAR
View our conference coverage. Do you know a conference you think we should list? Let us know by sending us an email with the details to conferences@alzforum.org. STUNNING DIAGNOSTIC ACCURACY FROM A PLASMA PROTEIN PANEL 1 day ago · Blood tests in development for Alzheimer’s disease rely on Aβ and phosphorylated tau, markers of its hallmark pathologies. While powerful, these markers are only accurate in about 90 percent of cases. Now, a new study suggests that a broad protein panel can do better, and allow clinicians toPAPERS | ALZFORUM
1 day ago · Maksimovich IV, Polyaev YA.The Importance of Early Diagnosis of Dyscircular Angiopathy of Alzheimer's Type in the Study of Heredity of Alzheimer's Disease.PAPERS | ALZFORUM
1 day ago · Ishii T.Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol. 1966 Mar 4;6(2):181-7.GV-971 | ALZFORUM
Overview. Name: GV-971 Synonyms: sodium oligomannate, sodium oligo-mannurarate Therapy Type: Small Molecule Target Type: Amyloid-Related , Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Status in Select Countries: Approved in China Company: Shanghai Green Valley Pharmaceuticals Background. This mixture of acidic linear oligosaccharides is derivedTG2576 | ALZFORUM
The Tg2576 model is one of the most well characterized, and widely used, mouse models of AD. It overexpresses a mutant form of APP (isoform 695) with the Swedish mutation (KM670/671NL), resulting in elevated levels of Aβ and ultimately amyloid plaques. The Tg2576 model was developed by Karen Hsiao Ashe and is now distributed throughTaconic
PAPERS | ALZFORUM
1 day ago · Ranlov P.The adoptive transfer of experimental mouse amyloidosis by intravenous injections of spleen cell extracts from casein-treated syngeneic donor mice. ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Algorithm Bests Humans in Predicting Alzheimer’s. Add To My AlzForum. 27 May 2021. A person's blood phospho-tau level, combined with his or her APOE genotype and scores on executive function and memory tests, outperforms the clinician in predicting dementia within the next four years. As Mice Age, T Cells Traipse Around TheirMeninges.
DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologicPOSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA.ATH-1017 | ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the biotechSEMORINEMAB
Overview. Name: Semorinemab Synonyms: RO7105705 , MTAU9937A, RG6100 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AC Immune SA, Genentech, Hoffmann-La Roche Background. This is an anti-tau IgG4 antibody that grew out of a research collaboration between AC Immune and LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.GANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aAMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion of INGESTED AΒ TRIPS TRANSFORMATION IN MICROGLIA A fluorescent dye, X04 binds Aβ fibrils. Grubman and colleagues extracted the animals’ brains two hours later, and used fluorescence-activated cell sorting to isolate microglia with and without the dye. They found that 13.5 and 15.8 percent of microglia were actively gobbling Aβ in the brains of 4- and 6-month-old mice,respectively.
ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Algorithm Bests Humans in Predicting Alzheimer’s. Add To My AlzForum. 27 May 2021. A person's blood phospho-tau level, combined with his or her APOE genotype and scores on executive function and memory tests, outperforms the clinician in predicting dementia within the next four years. As Mice Age, T Cells Traipse Around TheirMeninges.
DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologicPOSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA.ATH-1017 | ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the biotechSEMORINEMAB
Overview. Name: Semorinemab Synonyms: RO7105705 , MTAU9937A, RG6100 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AC Immune SA, Genentech, Hoffmann-La Roche Background. This is an anti-tau IgG4 antibody that grew out of a research collaboration between AC Immune and LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.GANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aAMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion of INGESTED AΒ TRIPS TRANSFORMATION IN MICROGLIA A fluorescent dye, X04 binds Aβ fibrils. Grubman and colleagues extracted the animals’ brains two hours later, and used fluorescence-activated cell sorting to isolate microglia with and without the dye. They found that 13.5 and 15.8 percent of microglia were actively gobbling Aβ in the brains of 4- and 6-month-old mice,respectively.
ALL NEWS | ALZFORUM
iNDI Aims to Standardize Human Stem Cell Research. Add To My AlzForum. 06 May 2021. The iPSC Neurodegenerative Disease Initiative is creating 100+ isogenic cell lines. Each carries a different risk variant for Alzheimer's or a related dementia. Scientists around the world can obtain the cells through Jackson Labs.ALL NEWS | ALZFORUM
Aducanumab Approved to Treat Alzheimer’s Disease. Add To My AlzForum; 17 Comments; 07 Jun 2021. Biogen got the go-ahead under the FDA’s accelerated approval pathway, which requires change in a surrogate biomarker and Phase 4 studies to verify a clinical benefit.ALL NEWS | ALZFORUM
Neuronal Exosomes Embroiled in Controversy. Add To My AlzForum; 3 Comments; 10 Jun 2021. The L1CAM cell adhesion marker is a widelyadopted marker of
CONFERENCE CALENDAR
View our conference coverage. Do you know a conference you think we should list? Let us know by sending us an email with the details to conferences@alzforum.org. STUNNING DIAGNOSTIC ACCURACY FROM A PLASMA PROTEIN PANEL 1 day ago · Blood tests in development for Alzheimer’s disease rely on Aβ and phosphorylated tau, markers of its hallmark pathologies. While powerful, these markers are only accurate in about 90 percent of cases. Now, a new study suggests that a broad protein panel can do better, and allow clinicians toPAPERS | ALZFORUM
1 day ago · Maksimovich IV, Polyaev YA.The Importance of Early Diagnosis of Dyscircular Angiopathy of Alzheimer's Type in the Study of Heredity of Alzheimer's Disease.PAPERS | ALZFORUM
1 day ago · Ishii T.Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol. 1966 Mar 4;6(2):181-7.GV-971 | ALZFORUM
Overview. Name: GV-971 Synonyms: sodium oligomannate, sodium oligo-mannurarate Therapy Type: Small Molecule Target Type: Amyloid-Related , Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Status in Select Countries: Approved in China Company: Shanghai Green Valley Pharmaceuticals Background. This mixture of acidic linear oligosaccharides is derivedTG2576 | ALZFORUM
The Tg2576 model is one of the most well characterized, and widely used, mouse models of AD. It overexpresses a mutant form of APP (isoform 695) with the Swedish mutation (KM670/671NL), resulting in elevated levels of Aβ and ultimately amyloid plaques. The Tg2576 model was developed by Karen Hsiao Ashe and is now distributed throughTaconic
PAPERS | ALZFORUM
1 day ago · Ranlov P.The adoptive transfer of experimental mouse amyloidosis by intravenous injections of spleen cell extracts from casein-treated syngeneic donor mice. ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Algorithm Bests Humans in Predicting Alzheimer’s. Add To My AlzForum. 27 May 2021. A person's blood phospho-tau level, combined with his or her APOE genotype and scores on executive function and memory tests, outperforms the clinician in predicting dementia within the next four years. As Mice Age, T Cells Traipse Around TheirMeninges.
POSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA. DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologicATH-1017 | ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
SEMORINEMAB
Overview. Name: Semorinemab Synonyms: RO7105705 , MTAU9937A, RG6100 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AC Immune SA, Genentech, Hoffmann-La Roche Background. This is an anti-tau IgG4 antibody that grew out of a research collaboration between AC Immune and3XTG | ALZFORUM
Deficits are observed in both spatial and contextual based paradigms. At age 6.5 months, 3xTg mice displayed learning and memory deficits in the Barnes maze, but performed better than B6129SF2 wild-type mice in the Y maze and fear conditioning tasks ( Stover et al., 2015 ). Clearance of intraneuronal Aβ by immunotherapy rescues the early LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.GANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aAMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion of FORGET TYPICAL ALZHEIMER'S: AI FINDS FOUR TYPES. Women were less likely to be S4. Slippery Subtype Slopes. Regardless of clinical diagnosis, the rate of decline on the MMSE was different for the four subtypes. People classified as S3 (orange) declined more slowly than those subtyped as S1 (blue), S2 (green) or S4 (purple). S4s worsened fastest. ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Algorithm Bests Humans in Predicting Alzheimer’s. Add To My AlzForum. 27 May 2021. A person's blood phospho-tau level, combined with his or her APOE genotype and scores on executive function and memory tests, outperforms the clinician in predicting dementia within the next four years. As Mice Age, T Cells Traipse Around TheirMeninges.
POSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA. DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologicATH-1017 | ALZFORUM
NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
SEMORINEMAB
Overview. Name: Semorinemab Synonyms: RO7105705 , MTAU9937A, RG6100 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AC Immune SA, Genentech, Hoffmann-La Roche Background. This is an anti-tau IgG4 antibody that grew out of a research collaboration between AC Immune and3XTG | ALZFORUM
Deficits are observed in both spatial and contextual based paradigms. At age 6.5 months, 3xTg mice displayed learning and memory deficits in the Barnes maze, but performed better than B6129SF2 wild-type mice in the Y maze and fear conditioning tasks ( Stover et al., 2015 ). Clearance of intraneuronal Aβ by immunotherapy rescues the early LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.GANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aAMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion of FORGET TYPICAL ALZHEIMER'S: AI FINDS FOUR TYPES. Women were less likely to be S4. Slippery Subtype Slopes. Regardless of clinical diagnosis, the rate of decline on the MMSE was different for the four subtypes. People classified as S3 (orange) declined more slowly than those subtyped as S1 (blue), S2 (green) or S4 (purple). S4s worsened fastest.ALL NEWS | ALZFORUM
iNDI Aims to Standardize Human Stem Cell Research. Add To My AlzForum. 06 May 2021. The iPSC Neurodegenerative Disease Initiative is creating 100+ isogenic cell lines. Each carries a different risk variant for Alzheimer's or a related dementia. Scientists around the world can obtain the cells through Jackson Labs.LOGIN | ALZFORUM
1 day ago · Don’t already have an account? Creating an account has many great benefits and features. Receive Notifications Find out when the topics & news articles you care about have new content.; Save Articles and Annotations Save news articles to your library for annotation and easy reference later.; Make Comments Post your comments on ALZFORUM content.; Join NowALL NEWS | ALZFORUM
No Breach Needed: Ultrasound Improves Memory in Mice. Add To My AlzForum; 04 Jun 2021. When pulsed through the skull, ultrasound restored synaptic signaling, neurogenesis, and memory, inALL NEWS | ALZFORUM
Anti-Tau Strategy PACs a Punch. Add To My AlzForum; 2 Comments; 03 Jun 2021. Activating the G protein-coupled receptor PAC1R in the mouseALL NEWS | ALZFORUM
Ingested Aβ Trips Transformation in Microglia . Add To My AlzForum; 4 Comments; 28 May 2021. In the plaque-ridden mouse brain, microglia that had taken up Aβ activated a unique gene-expression profile.ALL NEWS | ALZFORUM
Ibuprofen Linked to Reduced Alzheimer's Risk. Add To My AlzForum. 10 Mar 1997. Ibuprofen and related drugs may reduce a person’s risk of getting Alzheimer’s disease by 30 to 60 percent, according to a new study by researchers at Johns Hopkins University and ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the INGESTED AΒ TRIPS TRANSFORMATION IN MICROGLIA A fluorescent dye, X04 binds Aβ fibrils. Grubman and colleagues extracted the animals’ brains two hours later, and used fluorescence-activated cell sorting to isolate microglia with and without the dye. They found that 13.5 and 15.8 percent of microglia were actively gobbling Aβ in the brains of 4- and 6-month-old mice,respectively.
PAPERS | ALZFORUM
1 day ago · Földi M, Gellért A, Kozma M, Poberai M, Zoltán OT, Csanda E.New contributions to the anatomical connections of the brain and the lymphatic system. ALZFORUM | NETWORKING FOR A CURE BA, Northwestern University 2016 - Integrated Science, Biology. PhD, Stanford University, August 2021 - Genetics. Advised by Alice Ting ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Hans Zempel on Anti-Tau Strategy PACs a Punch 04 Jun 2021; Dezhi Liao on Anti-Tau Strategy PACs a Punch 04 Jun 2021; Bart De Strooper on Neurons Made from Fibroblasts Keep Imprint of Alzheimer's, Aging 03 Jun 2021; Mark Cookson, Michael Ward and Andrew Singleton on Neurons Made from Fibroblasts Keep Imprint of Alzheimer's, Aging 03 Jun 2021; Alberto Pascual and Javier Vitorica ALL NEWS | ALZFORUMPAPERSMEMBER DIRECTORYCONTACT USCONFERENCE COVERAGEANTIBODIESLOGIN iNDI Aims to Standardize Human Stem Cell Research. Add To My AlzForum. 06 May 2021. The iPSC Neurodegenerative Disease Initiative is creating 100+ isogenic cell lines. Each carries a different risk variant for Alzheimer's or a related dementia. Scientists around the world can obtain the cells through Jackson Labs.POSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA. DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic ATH-1017 | ALZFORUMNDX 1017 MECHANISMNDX 1017 MECHANISMNDX 1017 CHEMICAL STRUCTURENDX 1017 CHEMICAL STRUCTURE NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
3XTG | ALZFORUM
Deficits are observed in both spatial and contextual based paradigms. At age 6.5 months, 3xTg mice displayed learning and memory deficits in the Barnes maze, but performed better than B6129SF2 wild-type mice in the Y maze and fear conditioning tasks ( Stover et al., 2015 ). Clearance of intraneuronal Aβ by immunotherapy rescues the early ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.AMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion ofGANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to a ALZFORUM | NETWORKING FOR A CURELOGINABOUT USNEWSLETTERNEWSWEBINARSDATABASES Hans Zempel on Anti-Tau Strategy PACs a Punch 04 Jun 2021; Dezhi Liao on Anti-Tau Strategy PACs a Punch 04 Jun 2021; Bart De Strooper on Neurons Made from Fibroblasts Keep Imprint of Alzheimer's, Aging 03 Jun 2021; Mark Cookson, Michael Ward and Andrew Singleton on Neurons Made from Fibroblasts Keep Imprint of Alzheimer's, Aging 03 Jun 2021; Alberto Pascual and Javier Vitorica ALL NEWS | ALZFORUMPAPERSMEMBER DIRECTORYCONTACT USCONFERENCE COVERAGEANTIBODIESLOGIN iNDI Aims to Standardize Human Stem Cell Research. Add To My AlzForum. 06 May 2021. The iPSC Neurodegenerative Disease Initiative is creating 100+ isogenic cell lines. Each carries a different risk variant for Alzheimer's or a related dementia. Scientists around the world can obtain the cells through Jackson Labs.POSIPHEN | ALZFORUM
Background. Posiphen, also known as ANVS-401, is the pure (+) enantiomer of phenserine. Both compounds were originally developed by Torrey Pines Therapeutics and licensed to QR Pharma in 2008. Both Posiphen and phenserine reduce production of amyloid precursor protein by blocking translation of its mRNA. DONANEMAB | ALZFORUM Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic ATH-1017 | ALZFORUMNDX 1017 MECHANISMNDX 1017 MECHANISMNDX 1017 CHEMICAL STRUCTURENDX 1017 CHEMICAL STRUCTURE NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system. HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory ( Akimoto et al., 2004; Kato et al., 2012 ). NDX-1017 is being developed as asubcutaneous
3XTG | ALZFORUM
Deficits are observed in both spatial and contextual based paradigms. At age 6.5 months, 3xTg mice displayed learning and memory deficits in the Barnes maze, but performed better than B6129SF2 wild-type mice in the Y maze and fear conditioning tasks ( Stover et al., 2015 ). Clearance of intraneuronal Aβ by immunotherapy rescues the early ADUCANUMAB | ALZFORUM Overview. Name: Aducanumab Synonyms: BIIB037 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Neurimmune Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ. It was originally derived by the LECANEMAB | ALZFORUM Overview. Name: Lecanemab Synonyms: BAN2401 , mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils.AMX0035 | ALZFORUM
AMX0035 is a proprietary, oral combination of two drugs already in use, sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). PB is prescribed under the brand name Buphenyl to treat urea cycle disorders. It acts as a scavenger to facilitate the excretion ofGANTENERUMAB
Overview. Name: Gantenerumab Synonyms: RO4909832, RG1450 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Background. Gantenerumab is a fully human IgG1 antibody designed to bind with subnanomolar affinity to aALL NEWS | ALZFORUM
iNDI Aims to Standardize Human Stem Cell Research. Add To My AlzForum. 06 May 2021. The iPSC Neurodegenerative Disease Initiative is creating 100+ isogenic cell lines. Each carries a different risk variant for Alzheimer's or a related dementia. Scientists around the world can obtain the cells through Jackson Labs.ALL NEWS | ALZFORUM
Anti-Tau Strategy PACs a Punch. Add To My AlzForum; 03 Jun 2021. Activating the G protein-coupled receptor PAC1R in the mouse brain prompts the proteasome to clear tangles.ALL NEWS | ALZFORUM
No Breach Needed: Ultrasound Improves Memory in Mice. Add To My AlzForum; 04 Jun 2021. When pulsed through the skull, ultrasound restored synaptic signaling, neurogenesis, and memory, inLOGIN | ALZFORUM
6 hours ago · Don’t already have an account? Creating an account has many great benefits and features. Receive Notifications Find out when the topics & news articles you care about have new content.; Save Articles and Annotations Save news articles to your library for annotation and easy reference later.; Make Comments Post your comments on ALZFORUM content.; Join NowALL NEWS | ALZFORUM
Neurons Made from Fibroblasts Keep Imprint of Alzheimer's, Aging. Add To My AlzForum; 2 Comments; 03 Jun 2021. Unlike iPSC-derived neurons, those created directly from fibroblasts reflect the donor's age anddisease status.
THERAPEUTICS
Therapeutics. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.ALL NEWS | ALZFORUM
Ingested Aβ Trips Transformation in Microglia . Add To My AlzForum; 4 Comments; 28 May 2021. In the plaque-ridden mouse brain, microglia that had taken up Aβ activated a unique gene-expression profile.BRAIN BANKS
This database lists brain banks around the world that collect central nervous system tissue from various neurodegenerative diseases and normal aging controls. The banks share samples and attendant demographic and clinical information with qualified researchers worldwide. Many brain banks operate asPAPERS | ALZFORUM
HAYFLICK L.THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. Exp Cell Res. 1965 Mar;37:614-36. PubMed.. Login to Comment or Recommend; Rossner S, Hartlage-Ruebsamen M, Schilling S, Demuth HU.GV-971 | ALZFORUM
Overview. Name: GV-971 Synonyms: sodium oligomannate, sodium oligo-mannurarate Therapy Type: Small Molecule Target Type: Amyloid-Related , Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Status in Select Countries: Approved in China Company: Shanghai Green Valley Pharmaceuticals Background. This mixture of acidic linear oligosaccharides is derived * JUMP TO THE NAVIGATION Menu * LOGIN TO My AlzForum * JUMP TO THE Search FORMNEWS
SIGH OF RELIEF? LUNG EFFECTS OF LRRK2 INHIBITORS ARE MILD. * Add To My AlzForum* 3 comments
24 Apr 2020
In nonhuman primates, three classes of LRRK2 kinase inhibitor cause microscopic changes in lung morphology, but they are reversible and do not impair breathing. Parkinson’s programs remain on track. Α-SYNUCLEIN ANTIBODY MISSES PRIMARY, MAY HAVE SIGNAL ON SECONDARIES * Add To My AlzForum22 Apr 2020
The first topline Phase 2 results from an antibody targeting Parkinson’s pathology, Roche’s prasinezumab, were a mixed bag. Next steps are unclear. PARKINSON'S THERAPIES SEEK TO STEM PROGRESSION * Add To My AlzForum22 Apr 2020
Trialists are shooting new arrows at the disease, including compounds that tweak autophagy, neuroinflammation, and glycolipid recycling. WITH TREM2, TIMING IS EVERYTHING * Add To My AlzForum22 Apr 2020
In a mouse model of amyloidosis, human wild-type TREM2 kept Aβ deposition at bay early on, but this defense became overwhelmed as plaques grew. The R47H AD risk variant never offered protection early on, and made things worse later. AΒ IN LEWY BODY DISEASE: TWO DISEASES AT ONCE, OR ANOTHER BEASTENTIRELY?
* Add To My AlzForum* 1 comment
21 Apr 2020
For people with Parkinson’s, carrying Alzheimer’s genetic risk variants upped their odds of harboring Aβ and tau pathology and getting dementia. In people with DLB, Aβ plaques worsened tau and Lewy pathology, and cognition. KLOTHO VARIANT CUTS APOE4’S ALZHEIMER RISK BY A THIRD * Add To My AlzForum* 2 comments
17 Apr 2020
Massive meta-analysis finds the longevity gene’s VS haplotype staves off mild cognitive impairment and AD. It reduces amyloid burden. ‘WORKING FROM HOME’: DO GUT MICROBES HOLD SWAY OVER GLIA, AΒ? * Add To My AlzForum16 Apr 2020
Scientists report at AAT-AD/PD that they tightened a causal connection between gut microbes, microglial function, and protein deposits. Inmice, that is.
DOES ALZHEIMER’S START IN THE HEART OF THE CHOLINERGIC SYSTEM? * Add To My AlzForum* 1 comment
16 Apr 2020
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.View All News
VIRTUAL EXHIBIT HALL Alzforum encourages users to visit the Virtual Exhibit Hall , where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Dash Genomics, Inc., Abcam, BrainXell, and the Jackson Laboratory.SPOTLIGHT
SIGH OF RELIEF? LUNG EFFECTS OF LRRK2 INHIBITORS ARE MILD. Concern about morphological changes in the alveoli of the lung has deflated high hopes for LRRK2 inhibitors, which had shown promise for treating Parkinson’s and related disorders. Now, researchers report that all inhibitors of LRRK2 are likely causing these lung effects. Does this mean LRRK2 inhibitor programs have fizzled? Maybe not. The changes are mild, do not affect respiration, and disappear once treatment stops. Scientists think they may reflect a treatment effect. Clinical trials of these compounds will need to monitor lung function. COMPLETE COVERAGE OF FIRST VIRTUAL AAT-AD/PD CONFERENCE Caught in the COVID-19 pandemic, the second Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting switched to an online format, offered at a slight discount. Its combination of 250 prerecorded lectures and e-posters, as well as livestreamed discussions, “Meet-the-Professor” audio chats, and a virtual exhibit hall drew around 1,100 registrations. Speakers told Alzforum that the technical aspects of giving their talks worked smoothly, and they enjoyed being able to view talks of interest in what ordinarily would have been parallel sessions. That said, they also confessed to viewing far fewer talks and posters by their colleagues than they would have in a live setting. Work at home intruded, and they missed the in-person interaction that enables the full immersion experience of a real-life conference. Did AAT-AD/PD fly by in a surreal week? Maybe you didn’t "go" this time? Peruse Alzforum’s 12-part conference news series.Previous
* 1 (CURRENT)
* 2
Next
JOIN THE CONVERSATIONLATEST COMMENTS
* Bojan Shutinoski on Sigh of Relief? Lung Effects of LRRK2 Inhibitors are Mild.25 Apr 2020
* Matthias Ochs on Sigh of Relief? Lung Effects of LRRK2 Inhibitorsare Mild.
24 Apr 2020
* Derya Shimshek on Sigh of Relief? Lung Effects of LRRK2 Inhibitorsare Mild.
24 Apr 2020
* Alice Chen-Plotkin on Aβ in Lewy Body Disease: Two Diseases at Once, or Another Beast Entirely?22 Apr 2020
* Jürgen Götz on Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.21 Apr 2020
* Niklas Mattsson-Carlgren on Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis.21 Apr 2020
* Oskar Hansson on Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis.21 Apr 2020
* Dimitri Krainc on Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export.21 Apr 2020
* David Knopman on White matter hyperintensities mediate the association of nocturnal blood pressure with cognition.21 Apr 2020
* Preeti Khandelwal on Real-time nanoscale organization of amyloidprecursor protein.
20 Apr 2020
* Pim van Gool on Does Alzheimer’s Start in the Heart of theCholinergic System?
20 Apr 2020
* Carmela Abraham on Klotho Variant Cuts ApoE4’s Alzheimer Risk bya Third
17 Apr 2020
* Tenielle Porter and Simon Laws on Klotho Variant Cuts ApoE4’s Alzheimer Risk by a Third17 Apr 2020
* Patricio Opazo on Real-time nanoscale organization of amyloidprecursor protein.
17 Apr 2020
* Debarpita Saha on Real-time nanoscale organization of amyloidprecursor protein.
17 Apr 2020
* Kristine Freude on Real-time nanoscale organization of amyloidprecursor protein.
17 Apr 2020
* Anushree Bharadwaj on Real-time nanoscale organization of amyloidprecursor protein.
16 Apr 2020
* Brian Gordon on In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned13 Apr 2020
* Christoph Mark on Real-time nanoscale organization of amyloidprecursor protein.
13 Apr 2020
* Stephen Salloway on In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned10 Apr 2020
* Lon S. Schneider on In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned10 Apr 2020
View All Comments
PROFESSIONAL RESOURCESNew in last 7 days
* Grants
* NEW ITEMS: 4
* TOTAL ITEMS: 534
* Jobs
* NEW ITEMS: 1
* TOTAL ITEMS: 71
* Conference Calendar* NEW ITEMS: 3
* TOTAL ITEMS: 85
* Member Directory
Enter your keywords
* LOGIN
* HOME
* About Us
* Newsletter
* NEWS
* All News
* Conference Coverage* WEBINARS
* All Webinars
* Databases
* AlzBiomarker
* AlzPedia
* AlzRisk
* Antibodies
* Brain Banks
* Genetics
* AlzGene
* HEX
* Mutations
* Protocols
* Research Models
* Therapeutics
* PAPERS
* All Papers
* Papers of the Week* Milestone
* Alzforum Recommends * PROFESSIONAL RESOURCES * Conference Calendar* Grants
* Jobs
* Member Directory
* Virtual Exhibit Hall* ABOUT AD
* Research Timeline
* Clinical Trial Registries * Early Onset Familial * Films About Alzheimer's* MOOCs
* MY ALZFORUM
* My AlzForum Home
* View Library
* View Notifications* Set Notifications
* Edit Profile
Back to the Top
* Terms of Use
* How to Cite
* Privacy Policy
* Site Map
* Contact Us
Facebook Twitter
Linked In
RSS
Copyright © 1996–2020 FBRI LLC. All Rights Reserved. AlzBiomarker AlzRisk Antibodies Brain Banks Genetics AlzGene HEX Mutations Protocols Research Models TherapeuticsDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0